Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4
doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing
Remitting Multiple Sclerosis (RRMS). The trial will be conducted on an outpatient basis for
minimum treatment duration of 40 weeks.